Salix Pharmaceuticals says it has completed patient enrollment for the Phase III trial of its new drug Rifaximin. The company added that it expects to file an amendment to its new drug application for Rifaximin by November.

The study included 400 adults in four different countries and was designed to determine the effectiveness of the drug in the treatment of travelers’ diarrhea. Salix (Nasdaq: SLXP) said it had agreed to conduct the tests in order to compile more data based on discussions with the FDA as part of its NDA application.